Turning Strategy Into Seamless Execution
Direct-to-patient platforms like Lilly Direct, Hims & Hers, and Ro are redefining how care begins—compressing clinical evaluation, prescribing, and fulfillment into virtual-first experiences measured in days, not months. Driven by rising costs, access gaps, stigma, and one-click consumer expectations, these models are reshaping who initiates care, who owns the relationship, and where trust is built—forcing pharma to rethink how it engages patients and HCPs in a consumer-driven healthcare system.
- How social commerce, cash-pay pricing, and telehealth are converging to create a new care-access model—and what this signals about patient motivation, stigma, and unmet demand.
- What early direct-to-patient platforms are getting right when it comes to clinical oversight, equity, and HCP integration
- How pharma leaders can decide where to play (and where not to) as care goes direct
Check out the incredible speaker line-up to see who will be joining Brittney.
Download The Latest Agenda